 |
|
|
| |
Clinical Outcomes at Month 12 After Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND)
|
| |
| |
AIDS 2024 July 20-26 Munich
Stefan Schneider,1 Michael Sension,2 Alexandra Dretler,3 Sue Lalla-Reddy,4 Cathy Schubert,5 Deanna Merrill,5 David Richardson,6 Bintu Sherif,6 Laurie Zografos,6 Cindy Garris5
1Infectious Disease Specialists of Long Beach, Long Beach, CA, USA; 2Community AIDS Network (CAN) Community Health, Sarasota, FL, USA; 3Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 4Lalla-Reddy Medical Corporation, Fountain Valley, CA, USA; 5ViiV Healthcare, Durham, NC, USA; 6RTI Health Solutions, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
